Selects the Designed to Cure platform, which offers data integration, modelling and simulation capabilities
Biotechnology group Ipsen has agreed with French firm Dassault Systemes to use the firm's specialist software to accelerate its R&D and discovery of new therapeutics.
Ipsen has selected the 'Designed to Cure' platform, which offers data integration, modelling and simulation capabilities to gain a more comprehensive view of the dysregulations linked to diseases and improves and shortens the identification of higher quality drug candidates.
The project also aims to optimise the R&D processes of Ipsen’s multi-disciplinary teams located in France, the UK and the US, as well as those of its network of drug development partners including scientists, biotechs, clinical research organisations, and other stakeholders.
'After more than five years of partnering with Dassault Systèmes on bioIntelligence, we are pleased to achieve a key step in our collaboration with the deployment of this set of cutting edge innovative tools,' said Claude Bertrand, Executive Vice President, R&D and Chief Scientific Officer at Ipsen.
'The virtual world offers the pharmaceutical industry opportunities to reinvent collaboration, connect unrelated disciplines and simulate human biological complex phenomena like never before,' added Jean Colombel, Vice President, Life Sciences Industry, Dassault Systemes.